Find out about Professor Mark Lowdell's research on tumour-primed NK cells for acute myeloid leukaemia.
![](https://www.ucl.ac.uk/immunity-transplantation/sites/immunity_transplantation/files/styles/large_image/public/455-lowdell-nk.jpg?itok=eb4IytUr)
Overcoming NK cell resistance in tumours has been a goal of cancer immunotherapists for 30 years. Our patented technology uses a complex of tumour antigens and NK co-stimulatory molecules to prime resting NK cells t kill NK-resistant tumours including AML. These are being tested in clinical trials in the USA at present.
![](https://www.ucl.ac.uk/immunity-transplantation/sites/immunity_transplantation/files/styles/large_image/public/455-lowdell-nk-2.jpg?itok=3rQqOwuj)
The green fluorescence marks a recognition molecule at the synapses.
![](https://www.ucl.ac.uk/immunity-transplantation/sites/immunity_transplantation/files/styles/large_image/public/455-lowdell-nk-3.jpg?itok=ws6xLq2n)
Patients who make an NK immune response to their leukaemia after chemotherapy stay in remission, whereas those who don't relapse within two years.
![](https://www.ucl.ac.uk/immunity-transplantation/sites/immunity_transplantation/files/styles/large_image/public/455-lowdell-nk-4.jpg?itok=KjQFoD4l)
Some patients who were treated with TpNK in a phase 1 trial showed resolution of disease (CTI-03) or prolongation of remission (CTI-01, 04 and 11).